ProShare Advisors
PACB icon

ProShare Advisors’s Pacific Biosciences PACB Stock Holding History

ProShare Advisors’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$79.3K Sell
47,184
-6,351
-12% -$9.23K ﹤0.01% 1802
2026
Q1 		$70.7K Sell
53,535
-10,264
-16% -$18.4K ﹤0.01% 1752
2025
Q4 		$119K Buy
63,799
+5,883
+10% +$11.3K ﹤0.01% 1838
2025
Q3 		$74.1K Sell
57,916
-9,912
-15% -$13.4K ﹤0.01% 1886
2025
Q2 		$84.1K Sell
67,828
-3,744
-5% -$4.32K ﹤0.01% 1903
2025
Q1 		$84.5K Sell
71,572
-18,436
-20% -$28.3K ﹤0.01% 1872
2024
Q4 		$165K Buy
90,008
+22,215
+33% +$43.4K ﹤0.01% 1945
2024
Q3 		$115K Buy
67,793
+17,216
+34% +$28.3K ﹤0.01% 1855
2024
Q2 		$69.3K Sell
50,577
-13,493
-21% -$27.2K ﹤0.01% 1711
2024
Q1 		$240K Buy
64,070
+5,300
+9% +$31K ﹤0.01% 1562
2023
Q4 		$577K Buy
58,770
+9,023
+18% +$73.8K ﹤0.01% 962
2023
Q3 		$415K Buy
49,747
+84
+0.2% +$960 ﹤0.01% 1010
2023
Q2 		$661K Buy
49,663
+1,445
+3% +$17.6K ﹤0.01% 838
2023
Q1 		$558K Buy
48,218
+437
+0.9% +$4.34K ﹤0.01% 870
2022
Q4 		$391K Buy
47,781
+3,968
+9% +$34.2K ﹤0.01% 1087
2022
Q3 		$254K Sell
43,813
-2,716
-6% -$15.6K ﹤0.01% 1244
2022
Q2 		$206K Sell
46,529
-17,843
-28% -$108K ﹤0.01% 1459
2022
Q1 		$586K Sell
64,372
-14,651
-19% -$169K ﹤0.01% 1179
2021
Q4 		$1.62M Buy
79,023
+6,876
+10% +$166K ﹤0.01% 817
2021
Q3 		$1.84M Sell
72,147
-13,949
-16% -$413K 0.01% 731
2021
Q2 		$3.01M Buy
86,096
+10,662
+14% +$310K 0.01% 630
2021
Q1 		$2.51M Buy
75,434
+7,367
+11% +$258K 0.01% 630
2020
Q4 		$1.77M Buy
68,067
+19,125
+39% +$325K 0.01% 667
2020
Q3 		$483K Buy
48,942
+4,547
+10% +$26.2K ﹤0.01% 955
2020
Q2 		$153K Buy
44,395
+14,983
+51% +$51K ﹤0.01% 1517
2020
Q1 		$90K Sell
29,412
-22,977
-44% -$94.1K ﹤0.01% 1087
2019
Q4 		$269K Sell
52,389
-5,231
-9% -$26.6K ﹤0.01% 1409
2019
Q3 		$297K Sell
57,620
-1,584
-3% -$8.86K ﹤0.01% 1239
2019
Q2 		$358K Sell
59,204
-7,106
-11% -$49.8K ﹤0.01% 1154
2019
Q1 		$479K Buy
66,310
+1,420
+2% +$10.3K ﹤0.01% 1034
2018
Q4 		$480K Sell
64,890
-3,819
-6% -$24.2K ﹤0.01% 966
2018
Q3 		$372K Sell
68,709
-2,757
-4% -$11.8K ﹤0.01% 1246
2018
Q2 		$254K Sell
71,466
-3,716
-5% -$10.3K ﹤0.01% 1480
2018
Q1 		$154K Sell
75,182
-2,831
-4% -$7.35K ﹤0.01% 1590
2017
Q4 		$206K Buy
78,013
+5,784
+8% +$20.3K ﹤0.01% 1624
2017
Q3 		$379K Buy
72,229
+16,798
+30% +$72.2K ﹤0.01% 1065
2017
Q2 		$197K Sell
55,431
-3,263
-6% -$13.2K ﹤0.01% 1352
2017
Q1 		$303K Sell
58,694
-15,413
-21% -$75.4K ﹤0.01% 1244
2016
Q4 		$282K Buy
74,107
+8,300
+13% +$60.3K ﹤0.01% 1405
2016
Q3 		$590K Sell
65,807
-8,399
-11% -$70.2K 0.01% 888
2016
Q2 		$522K Buy
74,206
+7,057
+11% +$64.5K 0.01% 950
2016
Q1 		$571K Sell
67,149
-3,625
-5% -$35.7K 0.01% 938
2015
Q4 		$929K Buy
70,774
+7,814
+12% +$70.1K 0.01% 768
2015
Q3 		$230K Sell
62,960
-4,262
-6% -$20.8K ﹤0.01% 1251
2015
Q2 		$387K Sell
67,222
-3,451
-5% -$20K 0.01% 1204
2015
Q1 		$413K Buy
70,673
+11,065
+19% +$76.3K ﹤0.01% 1280
2014
Q4 		$467K Buy
59,608
+371
+0.6% +$2.37K 0.01% 1237
2014
Q3 		$291K Sell
59,237
-11,589
-16% -$60.6K ﹤0.01% 1740
2014
Q2 		$438K Sell
70,826
-28,272
-29% -$141K 0.01% 1668
2014
Q1 		$530K Buy
99,098
+66,400
+203% +$420K 0.01% 1824
2013
Q4 		$171K Sell
32,698
-20,595
-39% -$94.6K ﹤0.01% 1269
2013
Q3 		$295K Buy
53,293
+15,523
+41% +$53.9K 0.01% 1912
2013
Q2 		$95K Buy
+37,770
New +$94K ﹤0.01% 2269

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ProShare Advisors's PACB Position: Q2 2026 in Review

ProShare Advisors reduced its Pacific Biosciences (PACB) stake by 12% in Q2 2026, selling an estimated $9.23K and leaving 47,184 shares worth $79.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1802.

ProShare Advisors first reported a position in PACB in Q2 2013 and has held it in 53 quarters since. The position peaked at $3.01M in Q2 2021. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • ProShare Advisors held 47,184 shares of Pacific Biosciences worth $79.3K as of Q2 2026.
  • ProShare Advisors sold 6,351 Pacific Biosciences shares in Q2 2026, an estimated $9.23K.
  • Pacific Biosciences made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1802 holding.
  • ProShare Advisors first reported a position in Pacific Biosciences in Q2 2013 and has held it in 53 quarters since.
  • ProShare Advisors's Pacific Biosciences position peaked at $3.01M in Q2 2021.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.